1. Scrip
  2. >>Rare Diseases

Boehringer Targets High Unmet Need With Spesolimab Filing

Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares

 
• By Ayisha Sharma

Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.    

Generalized Pustular Psoriasis Presents High Unmet Need • Source: Alamy

Boehringer Ingelheim GmbH’s filing for spesolimab for generalized pustular psoriasis (GPP) flares has been accepted by the European Medicines Agency – in a first for this indication in Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.